Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.
Tanner M JohannsElizabeth A R GarfinkleKatherine E MillerAlexandra J LivingstoneKaleigh F RobertsLakshmi Prakruthi Rao VenkataJoshua L DowlingMichael R ChicoineRalph G DaceyGregory J ZipfelAlbert H KimElaine R MardisGavin P DunnPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Collectively, our findings suggest that NeoVax stimulated the expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine-based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in patients with GBM.